Pimecrolimus is a topical calcineurin inhibitor used to treat mild to moderate atopic dermatitis. It works by inhibiting t-cell activation which reduces inflammatory cytokines in the skin. The drug binds to fkbp12 and blocks calcineurin preventing transcription of pro-inflammatory genes. This results in decreased immune-mediated skin inflammation and itching. The medication is applied as a cream or ointment to affected areas twice daily. Minimal systemic absorption limits effects to the treated skin.

Pimecrolimus is a synthetic macrolactam immunosuppressant used primarily as a topical medication. It is applied to treat mild to moderate atopic dermatitis by reducing inflammation. The drug binds to the fkbp12 protein, forming a complex that blocks calcineurin activity. Inhibition of calcineurin prevents the transcription of interleukin-2, a cytokine that drives t-cell activation. This suppression of cytokine production leads to decreased inflammatory cell infiltration and reduced skin irritation. Consequently, Pimecrolimus provides anti-inflammatory effects without significant systemic immunosuppression when used topically.

Pimecrolimus may cause skin irritation at the application site in some people. Headache can occur occasionally during treatment. A mild burning or stinging sensation may be felt after use. Some users report feeling tired or experiencing mild flu like symptoms. Changes in skin color such as darkening or lightening can appear rarely. Overall the frequency of these reactions is considered low in most patients.

Pimecrolimus may cause mild skin irritation such as burning or tingling at the application site. Some users experience itching or redness that usually resolves after continued use. The medication can occasionally lead to contact dermatitis in sensitive individuals. These effects are generally mild and do not require medical intervention unless they persist. Patients may notice a temporary increase in skin sensitivity following application. Overall the reported side effects are typically limited to local skin responses. Long term use has not been linked to systemic adverse effects in most studies.